Navigation Links
GlaxoSmithKline 14th Annual IMPACT Awards Seek Greater Philadelphia and Camden Healthcare Nonprofits

PHILADELPHIA, Feb. 15 /PRNewswire-FirstCall/ -- The GlaxoSmithKline (NYSE: GSK) 14th Annual IMPACT Awards target community-based nonprofits that provide access to healthcare for the underserved. Up to ten organizations in the Pennsylvania counties of Berks, Bucks, Chester, Delaware, Lancaster, Lehigh, Montgomery, and Philadelphia and the City of Camden, New Jersey, will be awarded $40,000 each. The awards are bestowed upon winning organizations for success and achievements in their current, overall work, not just for new or specific initiatives. Applications will be accepted through March 29, 2010, 4:00 p.m. EDT.

Every year the GlaxoSmithKline IMPACT Awards acknowledge, highlight and reward nonprofit organizations that have a significant impact on their communities and are accomplished, proactive and effective in their work. GlaxoSmithKline's IMPACT Awards represent and support Innovation, Management, Partnership, Achievement, Community focus and Targeting needs within community-based healthcare organizations. Nonprofits that exemplify the IMPACT Awards criteria continue to provide quality, accessible healthcare to their communities despite their financial and resource limitations. Winners in previous years include organizations that provide medical and dental care for the underserved, access to care for the chronically ill, services for children with genetic disorders and comprehensive treatment for women with addiction.

To qualify for a GlaxoSmithKline IMPACT award, applicants must provide access to healthcare services (primary mission); have annual total operating expenses between $160,000 and $3 million, as documented in the organization's most recent fiscal year financial statement; and have been in existence as a 501(c)(3) nonprofit organization for at least five years. A panel of local and national healthcare delivery experts and GlaxoSmithKline representatives will determine the winners based on a strong demonstration of ongoing success in providing access to healthcare; commitment to serving people in need; facilitation of healthcare delivery, substantive partnerships; policy development; and a solid record of achievement, management and leadership.

The GlaxoSmithKline IMPACT Awards will be presented at an awards ceremony in Philadelphia in late 2010. For more details and to apply, please visit the GlaxoSmithKline site at and select "Our work with communities," then click "Health programs," then click "Awards," and finally click "Philadelphia region" or call GlaxoSmithKline Community Partnerships at 215-751-5171.

About GlaxoSmithKline: GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline on the World Wide Web at

SOURCE GlaxoSmithKline



SOURCE GlaxoSmithKline
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
2. GlaxoSmithKline Accelerates Review of Exelixis XL880
3. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
4. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
5. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
6. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
7. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
8. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
9. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
10. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
11. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
Post Your Comments:
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing an ... to overcome a rare and deadly chromosome abnormality. , After struggling since birth ...
(Date:10/13/2017)... ... 2017 , ... As health professionals work to improve their approach to healthcare, ... doing more than filling out a survey; in many cases health professionals and patients ... health care and research on the importance of active engagement with patients and members ...
(Date:10/13/2017)... ... ... The American Board of Family Medicine's (ABFM) Board of Directors has selected ... Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the position ... the end of 2018. Upon assuming the role of President and CEO on January ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... PurhealthRX ... CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will ... and providing a CBD form that can be easily incorporated into liquid products, while ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & ... and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to ... with elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded ...
Breaking Medicine News(10 mins):